<DOC>
	<DOC>NCT00943917</DOC>
	<brief_summary>The purpose of this study is to determine safety, efficacy and tolerability of various doses of ITCA 650 in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Males or females age 1870 years Type 2 diabetes mellitus for ≥ 6 months prior to Screening Visit 1 On a stable (&gt; 3 months prior to Screening Visit 1) treatment regimen of metformin monotherapy; Fasting plasma glucose &lt; 240 mg/dL at Screening Visit 1 HbA1c ≥ 7% and ≤ 10% at Screening Visit 1 Prior treatment with exenatide Treatment with any of the following antidiabetic agents within 3 months prior to Screening Visit 1: TZDs, sulfonylureas, DPP IV inhibitors, acarbose, or insulin (injected or inhaled) History of type 1 diabetes and/or history of diabetic ketoacidosis Body mass index ≥ 40 kg/m2; History of organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>